Daytime Cortisol Patterns Link to Cognitive Decline but Not Alzheimer’s Risk

A study published in JAMA Network Open reveals that daytime cortisol levels correlate with cognitive decline in older adults but do not directly predict Alzheimer’s disease risk, according to researchers at Rush University Medical Center. This finding contrasts with other research exploring how sleep and genetic factors may influence early brain changes linked to Alzheimer’s.

Cortisol and Cognitive Decline: A Biomarker, Not a Direct Predictor

The study, part of the Chicago Health and Aging Project, followed 3,895 older adults for up to 11 years, measuring salivary cortisol levels at waking, late afternoon, and evening. Black participants showed lower cortisol fluctuations and total daily levels compared to White participants, with Black individuals also experiencing faster cognitive decline.

Sleep Interventions Show Promise in Alzheimer’s Research

Meanwhile, a small study from Washington University School of Medicine found that a sleeping pill called suvorexant reduced levels of key Alzheimer’s proteins—amyloid and tau—in healthy volunteers. However, the study’s lead author, Brendan Lucey, cautioned against premature conclusions: We don’t yet know whether long-term use is effective in staving off cognitive decline.

The research builds on earlier findings that poor sleep exacerbates Alzheimer’s pathology. Lucey’s team previously showed that sleep deprivation increases amyloid and tau levels in the brain. The new study suggests that targeting sleep could be a viable strategy, but more research is needed to determine optimal dosing and long-term effects.

Genetics, Sleep, and Brain Health: A Complex Relationship

Genetic research from Edith Cowan University (ECU) adds another layer to the puzzle. A study published in Alzheimer’s & Dementia found that variants of the AQP4 gene—critical for brain fluid regulation—interact with sleep patterns to influence grey matter loss. Participants with certain AQP4 variants experienced faster cognitive decline when reporting shorter sleep durations.

What this shows is that rather than assuming everyone at risk follows the same pathway, a more targeted and personalized approach may be needed, said Dr. Tenielle Porter, a researcher involved in the study. The findings underscore the importance of sleep as a modifiable risk factor but also highlight the need for precision health strategies that consider genetic differences.

Neuroinflammation and the Role of Cortisol in Alzheimer’s

Other research, including a review in Nature, explores the link between neuroinflammation, cerebrospinal fluid (CSF) cortisol levels, and Alzheimer’s progression. While elevated cortisol has been associated with cognitive decline, the relationship remains complex.

Professor Simon Laws of ECU’s Centre for Precision Health noted that the interplay between stress, sleep, and genetics could explain why some individuals decline faster than others. This moves us closer to understanding why some people decline faster than others, even when they have similar risk on paper, he said.

What’s Next? Personalized Approaches and Larger Trials

Despite these insights, many questions remain. The small scale of some studies, such as the 38-participant trial on suvorexant, limits conclusions. Researchers urge caution in interpreting results and emphasize the need for larger, diverse cohorts to validate findings.

We don’t yet know whether long-term use is effective in staving off cognitive decline, and if it is, at what dose and for whom, Lucey reiterated. Meanwhile, the ECU team advocates for clinical trials that integrate genetic data to assess whether improving sleep can mitigate inherited Alzheimer’s risks.

As the field advances, the convergence of cortisol research, sleep science, and genetics offers a multifaceted approach to understanding and addressing cognitive decline. For now, the message is clear: sleep remains a critical, modifiable factor in brain health, but its role in Alzheimer’s prevention requires further exploration.